Pacific Biosciences of California Inc PACB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PACB is a good fit for your portfolio.
News
-
PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance
-
Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes
-
PacBio Grants Equity Incentive Award to New Employee
-
PacBio Announces PureTarget™ Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions
-
PacBio to Present at Upcoming Investor Conferences
-
PacBio Announces Fourth Quarter and Fiscal Year 2023 Financial Results
-
Experiential Marketing Firm VOLO Events Agency Wins Best Event Technology Award for PacBio Product Launch
-
PacBio Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale
Trading Information
- Previous Close Price
- $1.47
- Day Range
- $1.35–1.51
- 52-Week Range
- $1.25–14.55
- Bid/Ask
- $1.35 / $1.37
- Market Cap
- $364.41 Mil
- Volume/Avg
- 11.1 Mil / 10.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.86
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 796
- Website
- https://www.pacb.com
Comparables
Valuation
|
Metric
|
PACB
|
TWST
|
CTKB
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 134.95 |
Price/Book Value | 0.56 | 3.01 | 1.93 |
Price/Sales | 1.86 | 6.70 | 4.07 |
Price/Cash Flow | — | — | 49.78 |
Price/Earnings
PACB
TWST
CTKB
Financial Strength
|
Metric
|
PACB
|
TWST
|
CTKB
|
|---|---|---|---|
Quick Ratio | 7.03 | 5.31 | 5.67 |
Current Ratio | 7.81 | 5.98 | 6.97 |
Interest Coverage | −21.18 | −55,011.75 | −9.68 |
Quick Ratio
PACB
TWST
CTKB
Profitability
|
Metric
|
PACB
|
TWST
|
CTKB
|
|---|---|---|---|
Return on Assets (Normalized) | −15.38% | −19.59% | −0.05% |
Return on Equity (Normalized) | −41.87% | −24.08% | −0.06% |
Return on Invested Capital (Normalized) | −16.60% | −22.74% | −0.83% |
Return on Assets
PACB
TWST
CTKB
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Qhfjnnsb | Clzbjqz | $185.5 Bil | |
SYK
| Stryker Corp | Glcnhjyxfn | Ppcm | $128.2 Bil | |
MDT
| Medtronic PLC | Ktyxxzx | Hsmddw | $106.7 Bil | |
BSX
| Boston Scientific Corp | Kjcxmtrzc | Qgsfhgw | $99.0 Bil | |
DXCM
| DexCom Inc | Wlpnldph | Nxw | $53.1 Bil | |
EW
| Edwards Lifesciences Corp | Tskmwnvfj | Rhzrspz | $52.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Rzyvhltfl | Qsc | $25.0 Bil | |
ALGN
| Align Technology Inc | Nmgttchx | Drncnf | $23.5 Bil | |
PHG
| Koninklijke Philips NV ADR | Sfnmngxwz | Fyszlx | $18.9 Bil | |
PODD
| Insulet Corp | Phmbxbdnz | Ddwmb | $11.7 Bil |